Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hoth Therapeutics, Inc. (HOTH : NSDQ)

• Company Description    Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.69 Daily Weekly Monthly 20 Day Moving Average: 836,416 shares Shares Outstanding: 19.13 (millions) Market Capitalization: $13.20 (millions) Beta: 0.57 52 Week High: $2.12 52 Week Low: $0.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.51% -17.74% 12 Week -33.65% -38.67% Year To Date -30.30% -40.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 720 Monroe Street Suite E514 - Hoboken,NJ 07030 USA ph: 866-239-7459 fax: - investorrelations@hoththerapeutics.com https://hoththerapeutics.com

• General Corporate Information    Officers Robb Knie - Chief Executive Officer and President David Briones - Chief Financial Officer Wayne Linsley - Director David B. Sarnoff - Director Chris Camarra - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44148G204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 19.13 Most Recent Split Date: 10.00 (0.04:1) Beta: 0.57 Market Capitalization: $13.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.17 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 37.04% vs. Previous Quarter: -6.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -165.25 12/31/25 - -139.84 09/30/25 - -133.69 ROA 03/31/26 - -143.61 12/31/25 - -126.88 09/30/25 - -123.43 Current Ratio 03/31/26 - 3.39 12/31/25 - 4.72 09/30/25 - 8.81 Quick Ratio 03/31/26 - - 12/31/25 - 4.72 09/30/25 - 8.81 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.22 12/31/25 - 0.40 09/30/25 - 0.54 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©